-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42

Benzinga·05/11/2026 18:38:05
Listen to the news
Guggenheim analyst Brad Canino initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $42.